CN115261339B - 一种多重耐药序列383型肺炎克雷伯氏菌噬菌体及其应用 - Google Patents
一种多重耐药序列383型肺炎克雷伯氏菌噬菌体及其应用 Download PDFInfo
- Publication number
- CN115261339B CN115261339B CN202210997923.3A CN202210997923A CN115261339B CN 115261339 B CN115261339 B CN 115261339B CN 202210997923 A CN202210997923 A CN 202210997923A CN 115261339 B CN115261339 B CN 115261339B
- Authority
- CN
- China
- Prior art keywords
- phage
- klebsiella pneumoniae
- pkp383
- multiple drug
- cgmcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000588747 Klebsiella pneumoniae Species 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 229940079593 drug Drugs 0.000 title claims abstract description 23
- 238000004321 preservation Methods 0.000 claims abstract description 17
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 10
- 238000005336 cracking Methods 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 13
- 241000588748 Klebsiella Species 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000000645 desinfectant Substances 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 235000012041 food component Nutrition 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 241001323676 bacterium C6 Species 0.000 description 8
- 230000002101 lytic effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 235000010633 broth Nutrition 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 239000002351 wastewater Substances 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- ABUBSBSOTTXVPV-UHFFFAOYSA-H [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ABUBSBSOTTXVPV-UHFFFAOYSA-H 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 108010068385 carbapenemase Proteins 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000001066 phage therapy Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/40—Viruses, e.g. bacteriophages
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/381—Microorganisms
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/43—Solvents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10331—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Genetics & Genomics (AREA)
- Pest Control & Pesticides (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Agronomy & Crop Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dentistry (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种多重耐药序列383型肺炎克雷伯氏菌噬菌体及其应用。具体而言,本发明提供了一种噬菌体,其保藏编号为CGMCC No.45098。本发明还提供了所述的噬菌体在制备特异高效地裂解多重耐药序列383型肺炎克雷伯氏菌的试剂中的应用。本发明噬菌体可在短时间内大量增殖,并对温度和酸碱度具有良好的耐受性,可用于治疗由多重耐药序列383型肺炎克雷伯氏菌引起的肺炎。
Description
技术领域
本发明是关于一种克雷伯氏菌噬菌体(Klebsiella phage)及其应用,具体地说,是关于一种多重耐药序列383型肺炎克雷伯氏菌噬菌体及其应用,以及该噬菌体在制备用于治疗由多重耐药(multidrug-resistant,MDR)序列383型肺炎克雷伯氏菌(Klebsiellapneumoniae,Kpn)引起的肺炎的药物中的应用,属于生物技术领域。
背景技术
肺炎克雷伯氏菌是一种有荚膜、发酵乳糖、兼性厌氧的革兰氏阴性菌,可存在于人体胃肠道、呼吸道以及健康个体皮肤上。肺炎克雷伯氏菌在环境中也无处不在,是一种机会性病原体,可引起多种感染性疾病,包括肺炎、***、菌血症和肝脓肿等。近年来,肺炎克雷伯氏菌已成为世界上医院感染的主要原因之一,易感人群为免疫功能低下人群、新生儿和老年人。研究表明,在引起肺炎的多重耐药肺炎克雷伯氏菌中,序列383型Kpn为优势型别之一。
近年来肺炎克雷伯氏菌的病死率不断攀升,这可能与肺炎克雷伯氏菌的抗生素耐药形势相关。肺炎克雷伯氏菌可携带多种抗生素耐药基因,包括产超广谱β-内酰胺酶和碳青霉烯酶等,使得感染难以治愈。研究表明亚洲地区Kpn对头孢类药物如头孢他啶、头孢噻肟、头孢吡肟的耐药率高于60%,对碳青霉烯类药物如亚胺培南和美罗培南的耐药率亦高于50%。过去二十年中,出现了众多多重耐药甚至是极端耐药的肺炎克雷伯氏菌菌株。多重耐药菌株井喷式的爆发和极其迅速的全球传播形势,给临床治疗带来了极大挑战。
噬菌体是一种可以特异性杀死细菌的病毒,对抗生素耐药的细菌也同样可产生作用。近年来,人们对噬菌体疗法进行了大量的研究和临床试验。相比于传统抗菌药,噬菌体具有许多的优势,尤其是在特异性和生物安全性方面。噬菌体主要由蛋白质和核酸组成,可在不影响其他细菌、病毒或宿主细胞的情况下特异性裂解目标细菌,毒性很小或无毒,具有很好的临床应用前景。
因此,如果能提供一种可以特异性裂解序列383型MDR序列383型Kpn的噬菌体,将对由MDR序列383型Kpn所致肺炎的治疗具有重要意义。
发明内容
本发明的一个目的在于提供一种多重耐药序列383型肺炎克雷伯氏菌噬菌体。
本发明的另一目的在于提供所述噬菌体的相关应用。
本案发明人分离得到一株裂解性多重耐药肺炎克雷伯氏菌噬菌体,本发明中命名为pKp383。本发明的噬菌体pKp383已于2022年4月26日保藏于中国微生物菌种保藏管理委员会普通微生物中心(地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所),其保藏日期:2022年4月26日;分类命名为:克雷伯氏菌噬菌体(Klebsiella phage),保藏编号为CGMCC No.45098。本发明中亦称该菌为噬菌体pKp383。
具体而言,一方面,本发明提供了一种噬菌体,其保藏编号为CGMCCNo.45098。
另一方面,本发明提供了一种噬菌体制剂,其包括:保藏编号为CGMCCNo.45098的噬菌体,以及辅料。
根据本发明的具体实施方案,本发明的噬菌体制剂中,所述辅料包括用于维持菌体活性的营养组分。在一些具体实施方案中,所述辅料可以为LB培养基。在一些更具体实施方案中,所述的LB培养基中,胰蛋白胨10g/L;酵母提取物5g/L;氯化钠10g/L。
根据本发明的一些具体实施方案,本发明的噬菌体制剂为药物。
根据本发明的一些具体实施方案,本发明的噬菌体制剂为清洁剂或消毒剂。
另一方面,本发明提供了保藏编号为CGMCC No.45098的噬菌体用于体外裂解多重耐药序列383型肺炎克雷伯氏菌的应用。
在本发明的一些具体实施方案中,本发明对噬菌体pKp383的宿主谱进行了测定,测定结果表明,噬菌体pKp383可裂解6株多重耐药序列383型Kpn菌株。
另一方面,本发明提供了保藏编号为CGMCC No.45098的噬菌体在制备用于裂解多重耐药序列383型肺炎克雷伯氏菌的制剂中的应用。
另一方面,本发明提供了保藏编号为CGMCC No.45098的噬菌体在制备用于防治由多重耐药序列383型肺炎克雷伯氏菌引起的肺炎的药物中的应用。
本发明的噬菌体pKp383属长尾噬菌体,对环境有良好的耐受性,可在温度4-50℃和pH 6-10的条件下保持稳定效价。噬菌体与细菌的最佳感染复数为0.001。一步生长曲线表明,本发明的噬菌体pKp383的潜伏期为10分钟,爆发期在110分钟,随后进入平台期。本发明的噬菌体可以裂解MDR序列383型Kpn菌株,特别是对于序列383型菌株C6(Genebank号为JAJOVD000000000,为现有技术中的一株MDR Kpn菌株)。本发明的噬菌体pKp383在感染复数为10到10-5的范围内均可体外有效抑制多重耐药序列383型肺炎克雷伯氏菌的生长,对于开发治疗由MDR序列383型Kpn所致肺炎的药物具有重要意义。此外,为验证pKp383的特异性,我们还检测了其它6株噬菌体对菌株C6的裂解能力,结果显示仅pKp383可裂解菌株C6。
综上所述,本发明提供了一种噬菌体pKp383,其可以特异性裂解多重耐药序列383型肺炎克雷伯氏菌,且具有宿主谱广泛、裂解效力高、环境耐受力好的特点,对多重耐药序列383型肺炎克雷伯氏菌具有很好的抑制效果,具有良好的应用前景。
附图说明
图1所示为噬菌体pKp383的透射电镜图。
图2所示为噬菌体pKp383的温度耐受性测试图。
图3所示为噬菌体pKp383的酸碱度耐受性测试图。
图4所示为噬菌体pKp383的一步生长曲线图。
图5所示为噬菌体pKp383的对宿主菌C6的裂解曲线图。
图6所示为7株噬菌体对宿主菌C6的裂解能力测试图。
用于专利程序的生物材料保存:
本发明的噬菌体pKp383(因其对多重耐药序列383型Kpn菌株具有裂解能力,提交保藏时以pKp383的自命名登记):
保藏日期:2022年4月26日;
保藏单位:中国微生物菌种保藏管理委员会普通微生物中心(CGMCC);
保藏单位地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所
保藏编号:CGMCC No.45098;
分类命名:克雷伯氏菌噬菌体(Klebsiella phage)。
具体实施方式
为使本发明的技术方案和优点更加清楚,下面将结合附图与实施例对本发明作进一步地详细描述。
下述实施例中的实验方法,如无特殊说明,均为常规方法。下述实施例中所用的实验材料,如无特殊说明,均为常规生化试剂,均可通过商购获得。
实施例1、噬菌体pKp383的分离纯化与保藏
噬菌体分离液的制备:2021年6月,从北京地区采集50mL医院污水,作为噬菌体分离的样品。将污水以转速4000rpm离心20分钟,以去除大颗粒。上清液通过0.22μm微孔滤器过滤,去除细菌。得到噬菌体分离液。
噬菌体的分离:以MDR序列383型肺炎克雷伯氏菌C6为宿主菌株,在5mL LB培养基中加入50μL菌悬液和200μL噬菌体分离液,转速220rpm 37℃振荡培养4小时,将培养液以转速10000rpm离心2分钟,上清液使用0.22μm微孔滤器过滤。取100μL上清液,采用双层琼脂平板法进行噬菌斑筛选。
噬菌体的纯化:待双层琼脂平板在37℃孵箱中静置培养12-24小时后,用接种环挑取单个噬菌斑至LB液体培养基中,同时加入50μL宿主菌C6悬液,于37℃摇床中以转速220rpm振荡培养4小时,将培养液以转速10000rpm离心2分钟,收集上清液,使用0.22μm微孔滤器过滤。取100μL滤后上清液,采用双层琼脂平板法进行噬菌斑纯化。重复上述操作4-5次,直至出现形态均匀、一致的噬菌斑,即获得纯化的噬菌体。
本发明中,采用上述方法,获得一株噬菌体,本发明中命名为pKp383。
噬菌体pKp383的电镜下形态观察:在纯化后的噬菌体pKp383培养液中加入1%的氯仿、DNase和RNase。离心上述溶液后收集上清,加入10%的PEG8000,再次离心后以SM缓冲液重悬沉淀。再次加入1%的氯仿,离心后取上层水相,获得噬菌体悬液。将噬菌体悬液稀释至适当浓度后,沉降于铜网表面,用2%(wt./vol)的醋酸铀(pH为7.0)对噬菌体颗粒进行负染色,并在80KV下用透射电镜观察,找到单个噬菌体完整形态的视野后拍照记录。如图1所示,噬菌体pKp383为长尾噬菌体,其头部为二十面体,直径约76nm,尾部长约126nm。
经检测,本发明的噬菌体pKp383有良好的热稳定性和pH稳定性,可在温度4-50℃和pH 6-10的条件下保持稳定效价,噬菌体与细菌的最佳感染复数为0.001。噬菌体pKp383的潜伏期为10分钟,爆发时间为110分钟,随后进入平台期。
噬菌体pKp383可以裂解的MDR Kpn菌株C6(Genebank号为JAJOVD000000000)为序列383型。序列383型已被证明是肺炎相关的肺炎克雷伯氏菌分离株的普遍序列型。本发明的噬菌体pKp383已于2022年4月26日保藏于中国微生物菌种保藏管理委员会普通微生物中心(地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所),保藏日期:2022年4月26日,分类命名为:克雷伯氏菌噬菌体,保藏编号为CGMCC No.45098。本发明中亦称该菌为噬菌体pKp383。
实施例2、噬菌体pKp383的温度耐受性测试
分别取噬菌体悬液(参照实施例1中所制备)pKp383 1mL于4℃、10℃、20℃、30℃、40℃、50℃、60℃、70℃和80℃条件下孵育1小时,使用双层琼脂平板法测定噬菌体效价。
测试结果如图2所示,噬菌体pKp383有良好的热稳定性,在温度4-50℃的条件下均可保持稳定效价。
实施例3、噬菌体pKp383的酸碱度耐受性测试
将噬菌体pKp383分别接种于pH值为1、2、3、4、5、6、7、8、9、10、11、12、13和14的SM缓冲液中,37℃条件下孵育1小时,并使用双层琼脂平板法测定噬菌体效价。
测试结果如图3所示,噬菌体pKp383有良好的pH稳定性,在pH值为6-10的条件下均可保持稳定效价。
实施例4、噬菌体pKp383的最佳感染复数和一步生长曲线测试
最佳感染复数的测定:采用双层琼脂平板法确定最佳感染复数(MOI)。在对数期宿主菌C6中加入噬菌体pKp383的MOI分别为0.0001、0.001、0.01、0.1、1、10和100。混合振荡培养4h后,最佳MOI处理组噬菌体效价最高。测试结果显示,当感染复数为0.001时,噬菌体pKp383的效价最高,即最佳感染复数为0.001。
一步生长曲线的测定:将噬菌体pKp383在最佳MOI条件下侵染宿主菌株C6,振荡培养150分钟内每10分钟测定一次噬菌体效价。测试结果如图4所示,噬菌体pKp383的潜伏期为10分钟,爆发时间为110分钟,随后进入平台期。
实施例5、噬菌体pKp383对宿主菌C6的裂解能力及宿主谱测试
对宿主菌C6的裂解能力测定:在感染复数为10、1、0.1、0.01、0.001、0.0001、10-5、10-6、10-7和10-8条件下测定噬菌体pKp383对寄主菌株C6的裂解活性。振荡培养7小时期间,每小时用酶标仪检测OD600值1次。测定结果如图5所示,MOI为10到10-5时,pKp383完全抑制寄主菌株Kp C6,噬菌体pKp383对寄主菌株表现出良好的裂解能力。可作为治疗由MDR Kpn所致急性肺炎的候选噬菌体制剂。
宿主谱测定:以最佳感染复数的比例分别将噬菌体pKp383和6株序列383型MDRKpn混合振荡培养4小时,观察培养液。培养液澄清即为噬菌体pKp383可裂解该MDR Kpn。测定结果显示,噬菌体pKp383可裂解6株不同序列383型MDR Kpn,6株MDR Kpn的具体信息如表1所示。
表1
菌株编号 | 序列型 |
C6 | 383 |
Kp383-2 | 383 |
Kp383-3 | 383 |
Kp383-4 | 383 |
Kp383-5 | 383 |
Kp383-6 | 383 |
实施例6、噬菌体对宿主菌C6的裂解能力测试
在含50μL宿主菌C6悬液的7管5mL LB培养基中,分别加入200μL噬菌体pKp-1、pKp-2、pKp-3、pKp-4、pKp-5、pKp11和pKp383,于37℃摇床中以转速220rpm振荡培养。培养4小时后,观察培养液是否澄清。如图6所示,pKp-1、pKp-2、pKp-3、pKp-4、pKp-5和pKp11处理组的培养液浑浊,表明该6株噬菌体不能裂解宿主菌C6;而pKp383处理组的培养液澄清,表明pKp383可裂解宿主菌C6。
应当指出的是,以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种克雷伯氏菌噬菌体(Klebsiella phage),其保藏编号为CGMCC No.45098。
2.根据权利要求1所述的噬菌体,其在温度4-50℃和pH 6-10的条件下保持稳定效价。
3.一种噬菌体制剂,其包括:保藏编号为CGMCC No.45098的噬菌体,以及辅料。
4.根据权利要求3所述的噬菌体制剂,其中,所述辅料包括用于维持菌体活性的营养组分。
5.根据权利要求4所述的噬菌体制剂,其中,所述辅料为LB培养基。
6.根据权利要求3所述的噬菌体制剂,其为药物。
7.根据权利要求3所述的噬菌体制剂,其为清洁剂或消毒剂。
8.保藏编号为CGMCC No.45098的噬菌体用于体外裂解多重耐药序列383型肺炎克雷伯氏菌的应用。
9.保藏编号为CGMCC No.45098的噬菌体在制备用于裂解多重耐药序列383型肺炎克雷伯氏菌的制剂中的应用。
10.保藏编号为CGMCC No.45098的噬菌体在制备用于防治由多重耐药序列383型肺炎克雷伯氏菌引起的肺炎的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210997923.3A CN115261339B (zh) | 2022-08-19 | 2022-08-19 | 一种多重耐药序列383型肺炎克雷伯氏菌噬菌体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210997923.3A CN115261339B (zh) | 2022-08-19 | 2022-08-19 | 一种多重耐药序列383型肺炎克雷伯氏菌噬菌体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115261339A CN115261339A (zh) | 2022-11-01 |
CN115261339B true CN115261339B (zh) | 2024-02-06 |
Family
ID=83752997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210997923.3A Active CN115261339B (zh) | 2022-08-19 | 2022-08-19 | 一种多重耐药序列383型肺炎克雷伯氏菌噬菌体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115261339B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106434489A (zh) * | 2016-11-18 | 2017-02-22 | 中国人民解放军疾病预防控制所 | 一株高产酒肺炎克雷伯菌株及其应用 |
CN114381436A (zh) * | 2022-02-09 | 2022-04-22 | 首都儿科研究所 | 一种高产乙醇肺炎克雷伯菌噬菌体及其应用 |
-
2022
- 2022-08-19 CN CN202210997923.3A patent/CN115261339B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106434489A (zh) * | 2016-11-18 | 2017-02-22 | 中国人民解放军疾病预防控制所 | 一株高产酒肺炎克雷伯菌株及其应用 |
CN114381436A (zh) * | 2022-02-09 | 2022-04-22 | 首都儿科研究所 | 一种高产乙醇肺炎克雷伯菌噬菌体及其应用 |
Non-Patent Citations (1)
Title |
---|
Rongrong Zhang.Biological characteristics and genome analysis of a novel phage vB_KpnP_IME279 infecting Klebsiella pneumoniae.《Folia Microbiologica》.2020,第65卷第925-936页. * |
Also Published As
Publication number | Publication date |
---|---|
CN115261339A (zh) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6942858B1 (en) | Compositions containing bacteriophages and methods of using bacteriophages to treat infections | |
Edward | The pleuropneumonia group of organisms: a review, together with some new observations | |
Ubukata et al. | Transduction of drug resistance to tetracycline, chloramphenicol, macrolides, lincomycin and clindamycin with phages induced from Streptococcus pyogenes | |
WO2016122127A1 (ko) | 신규한 락토바실러스 브레비스 박테리오파지 Lac-BRP-1 및 이의 락토바실러스 브레비스 균 증식 억제 용도 | |
WO2016122128A1 (ko) | 신규한 락토바실러스 플랜타룸 박테리오파지 Lac-PLP-1 및 이의 락토바실러스 플랜타룸 균 증식 억제 용도 | |
CN114480299B (zh) | 一种蜡样芽胞杆菌噬菌体及其应用 | |
CN111481574B (zh) | 一种用于治疗仔猪腹泻的组合型噬菌体制剂 | |
CN116515768A (zh) | 一种铜绿假单胞菌噬菌体及其应用 | |
CN112322553B (zh) | 一种抗艰难梭菌的乳酸乳球菌及其应用 | |
CN115261339B (zh) | 一种多重耐药序列383型肺炎克雷伯氏菌噬菌体及其应用 | |
CN114381436B (zh) | 一种高产乙醇肺炎克雷伯菌噬菌体及其应用 | |
Mitsuhashi et al. | Drug resistance of Enteric bacteria IX. Distribution of R factors in Gram-negative bacteria from clinical sources | |
CN108795859A (zh) | 红色诺卡氏菌细胞壁骨架作为自然杀伤细胞增殖促进剂的用途 | |
CN115125216B (zh) | 一种耐甲氧西林金黄色葡萄球菌的噬菌体及其应用 | |
Digranes et al. | Characterization of Micrococcaceae from the urinary tract | |
RU2112800C1 (ru) | Штамм пилеспецифического бактериофага pseudomonas aeruginosa гнцпм n 03, используемый для приготовления лечебного препарата против синегнойной палочки | |
Boice | Evidence that Bacillus subtilis Bacteriophage SPO2 is Temperate and Heteroimmune to Bacteriophage φ105 | |
CN115161292B (zh) | 一种多重耐药序列11型肺炎克雷伯氏菌噬菌体及其应用 | |
CN111088182B (zh) | 一种溶血性曼氏杆菌及其应用 | |
CN118147090B (zh) | 一株同时裂解多株大肠杆菌和沙门氏菌的噬菌体及其应用 | |
CN117586966B (zh) | 一株耐酸碱产气荚膜梭菌噬菌体rdp-cp-22005及其应用 | |
CN115418355B (zh) | 一种迟缓葡萄球菌噬菌体及其分离方法与应用 | |
CN117467623A (zh) | 猪源非解乳糖链球菌噬菌体及其应用 | |
CN117925536A (zh) | 一种具有跨属裂解能力的产气荚膜梭菌噬菌体及其应用 | |
CN118406662A (zh) | 一种沙门氏菌噬菌体vB_SalP_LDW8及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |